Extending human IgG half-life using structure-guided design. Issue 7 (3rd October 2018)

• Record Type: Journal Article
• Authors: Booth, Brian J.; Ramakrishnan, Boopathy; Narayan, Kristin; Wollacott, Andrew M.; Babcock, Gregory J.; Shriver, Zachary; Viswanathan, Karthik
• Is Part Of: MAbs. Volume 10:Issue 7(2018)
• Page Start: 1098
• Page End: 1110
• Publication Date: 2018-10-03
• Subjects: Antibody -- half-life -- pharmacokinetics -- structure-guided engineering -- neonatal Fc receptor -- FcRn -- effector functions -- amino acid interaction network; Monoclonal antibodies -- Therapeutic use -- Periodicals; Monoclonal antibodies -- Periodicals; Antibodies, Monoclonal -- Periodicals; 616.0798
• DOI: 10.1080/19420862.2018.1490119
• Languages: English
• ISSNs: 1942-0862

Abstract

ABSTRACT: Engineering of antibodies for improved pharmacokinetics through enhanced binding to the neonatal Fc receptor (FcRn) has been demonstrated in transgenic mice, non-human primates and humans. Traditionally, such approaches have largely relied on random mutagenesis and display formats, which fail to address related critical attributes of the antibody, such as effector functions or biophysical stability. We have developed a structure- and network-based framework to interrogate the engagement of IgG with multiple Fc receptors (FcRn, C1q, TRIM21, FcγRI, FcγRIIa/b, FcγRIIIa) simultaneously. Using this framework, we identified features that govern Fc-FcRn interactions and identified multiple distinct pathways for enhancing FcRn binding in a pH-specific manner. Network analysis provided a novel lens to study the allosteric impact of half-life-enhancing Fc mutations on FcγR engagement, which occurs distal to the FcRn binding site. Applying these principles, we engineered a panel of unique Fc variants that enhance FcRn binding while maintaining robust biophysical properties and wild type-like binding to activating receptors. An antibody harboring representative Fc designs demonstrates a half-life improvement of > 9 fold in transgenic mice and > 3.5 fold in cynomolgus monkeys, and maintains robust effector functions such as antibody-dependent cell-mediated cytotoxicity and complement-dependent cytotoxicity.